DARZALEX ® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma

· First Phase 3 study showing addition of the CD38-directed antibody DARZALEX® to carfilzomib in combination with dexamethasone· Data selected as a Late-Breaking Abstract at ASH 2019
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news